公开(公告)号：US5871933A

公开(公告)日：1999-02-16

申请号：US483353

申请日：1995-06-07

Applicant: Gregory R. Reyes ,  Kenneth G. Hadlock

Inventor： Gregory R. Reyes ,  Kenneth G. Hadlock

IPC: A61K39/12 ,  A61K38/00 ,  A61K39/00 ,  A61P31/12 ,  C07K1/22 ,  C07K7/06 ,  C07K7/08 ,  C07K14/15 ,  C07K16/00 ,  C07K16/10 ,  C12N1/21 ,  C12N15/09 ,  C12P21/02 ,  C12R1/19 ,  G01N33/53 ,  G01N33/574 ,  G01N33/577 ,  A61K39/21 ,  C12Q1/68

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2740/14022 ,  Y10S435/974 ,  Y10S435/975

Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.

Abstract translation: 公开了新型HTLV-1和HTLV-II肽抗原用于筛选和确认HTLV-1和HTLV-II抗血清的诊断测定。 肽衍生自HTLV-1和HTLV-II gp46包膜蛋白的类似区域，并通过其与HTLV-II特异性单克隆抗体和HTLV-I和HTLV-II抗血清的免疫反应性来区分。 肽也可用于疫苗组合物。

公开(公告)号：US5871748A

公开(公告)日：1999-02-16

申请号：US697268

申请日：1996-08-21

Applicant: Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

Inventor： Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61P31/12 ,  A61P37/04 ,  C07K16/08 ,  C07K16/10 ,  A61K39/15 ,  C07K16/00 ,  C12N1/00 ,  C12N7/00

CPC classification number: C07K16/1036 ,  A61K39/12 ,  C07K16/08 ,  C07K16/081 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  A61K38/00 ,  A61K39/00 ,  C12N2720/10034 ,  Y10S435/948

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

公开(公告)号：US5827750A

公开(公告)日：1998-10-27

申请号：US708107

申请日：1996-08-08

Applicant: Sidney E. Grossberg ,  Vladimir M. Kushnaryov ,  L. William Cashdollar ,  Donald R. Carrigan ,  Konstance K. Knox

Inventor： Sidney E. Grossberg ,  Vladimir M. Kushnaryov ,  L. William Cashdollar ,  Donald R. Carrigan ,  Konstance K. Knox

IPC: A61K39/21 ,  C07K14/15 ,  C07K16/10 ,  C12N7/00 ,  G01N33/569 ,  G01N33/53 ,  C12N5/00 ,  G01N33/531

CPC classification number: G01N33/56983 ,  C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N2740/10021 ,  C12N2740/10022

Abstract: A method for the detection of the presence or absence of antibodies which bind to antigens of an NMA virus indicative of Chronic Fatigue Immune Deficiency Syndrome is disclosed. This method comprises contacting a solution containing antigens of an NMA virus with a biological sample of a patient and detecting the antibody-antigen complexes. Methods for detection of the presence or absence of antigens or nucleic acid sequences specific to an NMA virus are also disclosed. A substantially purified preparation of an NMA virus and a human cell line chronically infected with an NMA virus are also disclosed.

Abstract translation: 公开了一种用于检测结合指示慢性疲劳免疫缺陷综合征的NMA病毒的抗原的抗体的存在或不存在的方法。 该方法包括将含有NMA病毒抗原的溶液与患者的生物样品接触并检测抗体 - 抗原复合物。 还公开了检测NMA病毒特异性的抗原或核酸序列的存在或不存在的方法。 还公开了NMA病毒和长期感染NMA病毒的人类细胞系的基本上纯化的制剂。

公开(公告)号：US5814441A

公开(公告)日：1998-09-29

申请号：US481598

申请日：1995-06-07

Applicant: Gregory R. Reyes ,  Kenneth G. Hadlock

Inventor： Gregory R. Reyes ,  Kenneth G. Hadlock

IPC: A61K39/12 ,  A61K38/00 ,  A61K39/00 ,  A61P31/12 ,  C07K1/22 ,  C07K7/06 ,  C07K7/08 ,  C07K14/15 ,  C07K16/00 ,  C07K16/10 ,  C12N1/21 ,  C12N15/09 ,  C12P21/02 ,  C12R1/19 ,  G01N33/53 ,  G01N33/574 ,  G01N33/577 ,  C12Q1/70 ,  G01N33/564 ,  G01N33/567

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2740/14022 ,  Y10S435/974 ,  Y10S435/975

Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.

公开(公告)号：US5397696A

公开(公告)日：1995-03-14

申请号：US743518

申请日：1991-08-12

Applicant: Richard Yanagihara ,  Vivek R. Nerurkar ,  Carol Jenkins ,  Mark Miller ,  Ralph M. Garruto

Inventor： Richard Yanagihara ,  Vivek R. Nerurkar ,  Carol Jenkins ,  Mark Miller ,  Ralph M. Garruto

IPC: A61K39/00 ,  C07K14/15 ,  C07K16/10 ,  C12N7/00 ,  C12N7/02

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  A61K39/00 ,  C12N2510/00 ,  C12N2740/14021 ,  C12N2740/14022

Abstract: The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian populations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.

Abstract translation: 本发明涉及持续感染巴布亚新几内亚（PNG）HTLV-1变体和感染病毒（PNG-1变体）的人T细胞系（PNG-1）。 本发明的细胞表达病毒抗原，C型粒子并具有低水平的逆转录酶活性。 这种细胞系的建立是来自巴布亚新几内亚的第一种细胞系，使得可以使用当地病毒株筛选美拉尼西亚人群。 本发明还涉及用于人类针对感染的疫苗和由HTLV-1和相关病毒引起的疾病。 本发明还涉及用于检测和诊断由HTLV-1和相关病毒引起的感染和疾病的各种生物测定和试剂盒。

公开(公告)号：US4855235A

公开(公告)日：1989-08-08

申请号：US758224

申请日：1985-07-08

Applicant: Toshitada Takahashi ,  Ryuzo Ueda ,  Kazuo Ohta

Inventor： Toshitada Takahashi ,  Ryuzo Ueda ,  Kazuo Ohta

IPC: G01N33/577 ,  A61K39/395 ,  C07K14/005 ,  C07K14/15 ,  C07K14/195 ,  C07K16/00 ,  C07K16/10 ,  C07K16/30 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/569

CPC classification number: G01N33/56972 ,  C07K16/1036 ,  C07K16/3061 ,  Y10S436/811 ,  Y10S530/864

Abstract: Monoclonal antibodies, Ta60b(Ferm BP-2170) and Ts145(Ferm BP-2171), are used for detecting human leukocyte antigens such as T cell differentiation antigens and T cell subset antigens.

Abstract translation: PCT No.PCT / JP84 / 00120 Sec。 371日期：1985年7月8日 102（e）日期1985年7月8日PCT提交1984年3月23日PCT公布。 出版物WO85 / 02188 日期：1985年5月23日。单克隆抗体Ta60b（Ferm BP-2170）和Ts145（Ferm BP-2171）用于检测人白细胞抗原如T细胞分化抗原和T细胞亚群抗原。

公开(公告)号：US20190010238A1

公开(公告)日：2019-01-10

申请号：US16031418

申请日：2018-07-10

Applicant: NEW YORK UNIVERSITY

Inventor： Thomas WISNIEWSKI ,  Allal BOUTAJANGOUT

IPC: C07K16/28 ,  C07K16/10 ,  A61P25/28 ,  A61P25/18

CPC classification number: C07K16/2872 ,  A61K2039/505 ,  A61P25/18 ,  A61P25/28 ,  C07K16/1036 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/34

Abstract: The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

公开(公告)号：US08541553B2

公开(公告)日：2013-09-24

申请号：US12601780

申请日：2008-05-23

Applicant: Johannes Humer ,  Bernd Mayer ,  Thomas Muster ,  Andrea Waltenberger

Inventor： Johannes Humer ,  Bernd Mayer ,  Thomas Muster ,  Andrea Waltenberger

IPC: C07K16/00 ,  C12N5/07 ,  A61K39/42 ,  A61K39/21

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.

Abstract translation: 本发明提供用于分离和/或鉴定内源性逆转录病毒，优选黑素瘤相关内源性逆转录病毒的表位的抗体或其片段，以及产生所述抗体的杂交瘤细胞。 抗体特别适用于癌症的治疗和诊断。 此外，本申请包括用于检测癌细胞，特别是黑素瘤细胞的诊断试剂盒和使用所述抗体的癌症诊断方法。

公开(公告)号：US20120171235A1

公开(公告)日：2012-07-05

申请号：US13414356

申请日：2012-03-07

Applicant: Xiaoxing Qiu ,  John R. Hackett, JR. ,  Ka-Cheung X. Luk ,  Priscilla Swanson

Inventor： Xiaoxing Qiu ,  John R. Hackett, JR. ,  Ka-Cheung X. Luk ,  Priscilla Swanson

IPC: A61K39/21 ,  A61P31/14 ,  A61P37/04

CPC classification number: C07K16/1036 ,  A61K39/00 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C12N2740/13022

Abstract: The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities.

Abstract translation: 本发明一般涉及用于检测嗜酸性白血病病毒相关逆转录病毒（“XMRV”）和与XMRV感染有关的疾病的检测方法。 此外，本发明涉及能够诱导免疫原性应答的特异性XMRV抗原以及具有显着诊断，筛选和治疗效用的XMRV相关核酸。

公开(公告)号：US20110243962A1

公开(公告)日：2011-10-06

申请号：US12997486

申请日：2009-07-08

Applicant: Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

Inventor： Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

IPC: A61K39/42 ,  C07K16/10 ,  C07H21/04 ,  A61P37/04 ,  A61P31/12 ,  A61P25/00 ,  A61P25/18 ,  A61P17/06 ,  A61P35/00 ,  A61P3/10 ,  C12N15/63 ,  C12P21/02 ,  G01N33/566 ,  C12N5/10

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

Abstract translation: 本发明涉及包含SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5所示的每个互补决定区（CDR）和 SEQ ID No.6或在所述序列中具有任意数目的取代氨基酸的序列，如下所示，CDR1（SEQ ID No.1）中为0至3，CDR2（SEQ ID No.2）为0至2， 在CDR3（SEQ ID No.3）中为0至2，CDR4（SEQ ID No.4）为0至1，CDR5（SEQ ID No.5）为0至4，CDR6（SEQ ID NO：0）为0至2 SEQ ID NO：6），或在所述序列SEQ ID No.1至SEQ ID No.6内具有等同化学功能和性质的其它氨基酸取代的氨基酸。